Similarly, the N-terminal of LAMP2B fused with interleukin-3 receptor (IL-3Rα) improved exosome-targeting efficiency at treating chronic myeloid leukemia (CML) [51]. This evidence concerns the gene IL3RA and chronic myelogenous leukemia, BCR-ABL1 positive.